We are monitoring the impact of COVID-19 on Europe Hemophilia Management Market Get in touch with us for detailed analysis Know More
Share on

Europe Hemophilia Management Market Research Report – Segmented By Type, Drug & By Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) – Analysis on Size, Share, Trends, Growth, Forecasts (2022 to 2027)

Published: January, 2022
ID: 272
Pages: 141

Europe Hemophilia Management Market Size (2022 to 2027)

As per our report, the size of the Europe Hemophilia Management Market was worth USD 1299.71 million in 2022 and estimated to be growing at a CAGR of 1.54%, to reach USD 1402.92 million by 2027.

Various factors that influence the growth of the European hemophilia management market include the increasing prevalence of hemophilia disorder, well-developed healthcare infrastructure, favorable health insurance, and supportive healthcare awareness programs to educate the population. The most common type of hemophilia reported is hemophilia A, which is due to the deficiency of coagulation factor VIII, the prevalence in the UK is recorded between 1:5,000 and 1:10,000 men. While Hemophilia B, which is due to the deficiency of factor IX, is less common with a recorded prevalence between 1:35,000 and 1:50,000 men. Doctors estimate that hemophilia C affects around one in a million people. Still, it is much more common in specific populations, including the Ashkenazi Jewish community, affecting one in 450 people. Furthermore, the disease is mainly prevalent in the geriatric population, with a mortality rate of around 22% if left untreated. All this data suggests the demand for hemophilia management in Europe during the forecast period.

Untreated hemophilia can be a life-threatening disorder, which can lead to complications. However, these bleeding disorders can be treated with plasma-derived clotting factors, recombinant clotting derivatives, antifibrinolytics, fibrin sealants, etc. In addition, other factors like the rising healthcare expenditures, research and development activities associated with hemophilia, a growing trend in adopting technologically advanced treatment options, and the expansion of pharmaceutical companies into recombinant products resulting in the launch of new products will have a positive influence on the market.

However, factors such as higher prices associated with hemophilia treatment options, stringent FDA regulations regarding the drug approval process and absence of any permanent cure for hemophilia, and the presence of counterfeit drugs are hampering the growth of the European hemophilia management market over the forecast period.

This research report on the European hemophilia management market has been segmented and sub-segmented into the following categories:

By Type:

  • Hemophilia A
  • Hemophilia B

By Drug:

  • Octocogalfa
  • Nonacogalfa
  • Desmopressin
  • Other Drugs

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

The regional market in the United Kingdom holds the largest market share in the European hemophilia management market. This market growth can be attributed to the presence of more market players and well-developed healthcare institutions, increased prevalence of hemophilia, high disposable income, adequate reimbursement policies, early availability, and adoption of the latest medications. As a result, in 2020, the number of people in the UK diagnosed with a blood disorder has increased, with over 8,509 diagnosed with hemophilia.

The hemophilia management market in France and Germany are expected to witness significant growth over the forecasted period owing to the presence of better medical facilities, sufficient funding for clinical trials for research and development, increasing use of technologically advanced products for the treatment of hemophilia, and growing prevalence of this disease in the regions. A recent French study provided information that over 3,435 hemophiliacs showed a prevalence of around 6.25% for the overall population. Meanwhile, the prevalence of treated hemophilia A in Germany was recorded at over 3.58 cases per 100,000 persons, with a cumulative incidence of 0.34/100,000. And the prevalence of hemophilia B was reported to be around 0.62/100,000. Healthcare professionals focus on R&D-related studies to innovate new and better products with lesser side effects.

KEY MARKET PLAYERS:

Companies playing a promising role in the European hemophilia management market profiled in this report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma, and Swedish Orphan Biovitrum AB.

  1. Introduction

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

  1. Market Segmentation

                5.1 BY Type                                        

                                5.1.1 Hemophilia A                         

                                5.1.2 Hemophilia B                          

                5.2 By Drug                                        

                                5.2.1 Octocogalfa                            

                                5.2.2 Nonacogalfa                           

                                5.2.3 Desmopressin                       

                                5.2.4 Other drugs                            

  1. Geographical Analysis

                                6.1 Introduction                               

                                6.2 U.K                 

                                6.3 Spain                             

                                6.4 Germany                     

                                6.5 Italy                               

                                6.6 France                          

  1. Strategic Analysis

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

  1. Market Leaders' Analysis

                8.1 Biogen                                          

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                             

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Pfizer Inc.                                    

                8.3 Baxter International Inc.                                       

                8.4 Bayer Pharma AG                                    

                8.5 Novo Nordisk A/S                                    

                8.6 Grifols International SA                                         

                8.7 CSL Behring                                

                8.8 Octapharma                                               

                8.9 Swedish Orphan Biovitrum AB                                           

  1. Competitive Landscape

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

  1. Expert Opinions

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

     Appendix                                                          

a) List of Tables

b) List of Figures

  1. Europe Hemophilia Management Market By Region, From 2022 - 2027 (USD Million)
  2. Europe Hemophilia Management Market By Type, From 2022 - 2027 (USD Million)
  3. Europe Hemophilia-A Market By Region, From 2022 - 2027 (USD Million)
  4. Europe Hemophilia-B Market By Region, From 2022 - 2027 (USD Million)
  5. Europe Hemophilia Management Market By Drug, From 2022 - 2027 (USD Million)
  6. Europe Octocogalfa Market By Region, From 2022 - 2027 (USD Million)
  7. Europe Nonacogalfa Market By Region, From 2022 - 2027 (USD Million)
  8. Europe Desmopressin Market By Region, From 2022 - 2027 (USD Million)
  9. Europe Other drugs Market By Region, From 2022 - 2027 (USD Million)
  10. U.K Hemophilia Management Market By Type, From 2022 - 2027 (USD Million)
  11. U.K Hemophilia Management Market By Drug, From 2022 - 2027 (USD Million)
  12. Spain Hemophilia Management Market By Type, From 2022 - 2027 (USD Million)
  13. Spain Hemophilia Management Market By Drug, From 2022 - 2027 (USD Million)
  14. Germany Hemophilia Management Market By Type, From 2022 - 2027 (USD Million)
  15. Germany Hemophilia Management Market By Drug, From 2022 - 2027 (USD Million)
  16. Italy Hemophilia Management Market By Type, From 2022 - 2027 (USD Million)
  17. Italy Hemophilia Management Market By Drug, From 2022 - 2027 (USD Million)
  18. France Hemophilia Management Market By Type, From 2022 - 2027 (USD Million)
  19. France Hemophilia Management Market Market By Drug, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample